TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18432125

Group type: EXPERIMENTAL
Intervention: Sonotherapy (ultrasound)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 73
Study: 14736768

Group type: EXPERIMENTAL
Intervention: Hydrophilic hydrogel IOL
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL
Number of subjects: 95
Study: 11554015

Group type: EXPERIMENTAL
Intervention: Continuous heparin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no heparin infusion)
Number of subjects: 0
Study: 9699231

Group type: EXPERIMENTAL
Intervention: Mixed-model ANOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random coefficients model
Number of subjects: 0
Study: 8148280

Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg/day CyA
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg/day CyA
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: CyA (both doses)
Number of subjects: 251
Study: 3059891

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Continuous Positive Inspiratory Pressure (CPIP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Continuous Positive Expiratory Pressure (CPEP)
Number of subjects: 5
Study: 30044938

Group type: EXPERIMENTAL
Intervention: BCX7353 125 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: BCX7353 250 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: BCX7353 350 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 26565074

Group type: EXPERIMENTAL
Intervention: Home use of misoprostol
Number of subjects: 731

Group type: COMPARATOR
Intervention: Clinic use of misoprostol
Number of subjects: 731
Study: 25739969

Group type: EXPERIMENTAL
Intervention: Endoscopic RGB evaluation of tympanic membrane (TM) images in patients with OME
Number of subjects: 52

Group type: COMPARATOR
Intervention: Endoscopic RGB evaluation of tympanic membrane (TM) images in healthy controls
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Measurement of viscosity of effusion in patients with OME
Number of subjects: 52
Study: 23748750

Group type: EXPERIMENTAL
Intervention: Ticagrelor 400 mg qd
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Digoxin (0.25 mg bid on day 6 and 0.25 mg qd on days 7-14)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ticagrelor and digoxin co-administration
Number of subjects: 20
Study: 20965379

Group type: EXPERIMENTAL
Intervention: New Moves intervention (all-girls physical education class, nutrition and self-empowerment components, motivational interviewing, lunch meetings, parent outreach)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: New Moves intervention
Number of subjects: 356

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 356
Study: 19099634

Group type: EXPERIMENTAL
Intervention: High dose thalidomide (HD-T)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Thalidomide + VAD chemotherapy (T-VAD)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Thalidomide + MP chemotherapy (T-MP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Thalidomide + dexamethasone (TD)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low dose thalidomide (LD-T)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional VAD chemotherapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Adverse reactions in 5 groups
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Treatment-related mortality
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Serum levels of TNF-alpha in ineffective group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Serum levels of TNF-alpha in effective group
Number of subjects: 85
Study: 15119586

Group type: EXPERIMENTAL
Intervention: Air abrasion alone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prophylaxis followed by acid etching
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mechanical widening with bur and etching
Number of subjects: 90

Group type: COMPARATOR
Intervention: Air abrasion and etching
Number of subjects: 90
Study: 11413082

Group type: EXPERIMENTAL
Intervention: Deferral of PTCA
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Performance of PTCA
Number of subjects: 325

Group type: COMPARATOR
Intervention: Reference group (PTCA performed as planned)
Number of subjects: 325
Study: 9595974

Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg daily for 2 consecutive days every month for 6 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 26
Study: 8015122

Group type: EXPERIMENTAL
Intervention: Adequate method for generating a sequence of random numbers
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Concealment of assignment until treatment allocation
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both sequence generation and allocation concealment
Number of subjects: 206

Group type: COMPARATOR
Intervention: Unrestricted randomization
Number of subjects: 206

Group type: COMPARATOR
Intervention: Hypothesis tests for baseline characteristics
Number of subjects: 206
Study: 3220231

Group type: EXPERIMENTAL
Intervention: Fungal lipase (FL) (Rhizopus arrhizus)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Classical porcine pancreatic extract (Eurobiol)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29550783

Group type: EXPERIMENTAL
Intervention: 6-month targeted exercise training programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-month cognitive and social enrichment programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6-month stretch and tone programme (control)
Number of subjects: 0
Study: 27444251

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24687830

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1194
Study: 21992867

Group type: EXPERIMENTAL
Intervention: Polyethylene wrap with previous drying
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyethylene wrap without previous drying
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile preheated field (Control)
Number of subjects: 0
Study: 20399512

Group type: EXPERIMENTAL
Intervention: +3953TT in IL1B
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: ‐592C/A heterozygosity in IL10
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Other polymorphisms
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: IFNGR1 818del4 mutation
Number of subjects: 296
Study: 17917909

Group type: EXPERIMENTAL
Intervention: Subjective picture version
Number of subjects: 60

Group type: COMPARATOR
Intervention: Objective picture version
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subjective representations
Number of subjects: 60

Group type: COMPARATOR
Intervention: Objective representations
Number of subjects: 60
Study: 15863678

Group type: EXPERIMENTAL
Intervention: Methodological quality assessed using the Jadad score
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Ethical quality assessed using the Berdeu score
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Year of commencement of trials
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Correlation between methodological quality and number of participating patients
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Correlation between ethical quality and number of participating patients
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Correlation between ethical quality and methodological quality
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Obtaining ICP and REC approval
Number of subjects: 231
Study: 11157566

Group type: EXPERIMENTAL
Intervention: Sporadic Parkinson's disease
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Familial Parkinson's disease
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 9536525

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 0
Study: 7949271

Group type: EXPERIMENTAL
Intervention: Intensive Education (IE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual Education (UE)
Number of subjects: 104
Study: 2853751

Group type: EXPERIMENTAL
Intervention: Yohimbine infusion (3 micrograms/kg per min) during glucose infusion (20 min) in group I
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atenolol infusion (1 micrograms/kg per min) in group II
Number of subjects: 16
Study: 31339533

Group type: COMPARATOR
Intervention: Combat Application Tourniquet (CAT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Special Operation Forces Tactical Tourniquet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stretch‐Wrap‐and‐Tuck Tourniquet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Rapid Application Tourniquet System
Number of subjects: 102

Group type: COMPARATOR
Intervention: Improvised tourniquet
Number of subjects: 102
Study: 27943089

Group type: EXPERIMENTAL
Intervention: Diltiazem co-treatment with microemulsified cyclosporine-A (CsA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (without diltiazem)
Number of subjects: 39
Study: 25278482

Group type: EXPERIMENTAL
Intervention: Upper extremity ischemia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lower extremity ischemia
Number of subjects: 40
Study: 24761498

Group type: EXPERIMENTAL
Intervention: Latex agglutination test
Number of subjects: 80
Study: 22257497

Group type: EXPERIMENTAL
Intervention: Non‐adjuvanted whole‐virion H1N1 influenza vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: AS03B‐adjuvanted split‐virion H1N1 influenza vaccine
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine
Number of subjects: 318
Study: 19405858

Group type: EXPERIMENTAL
Intervention: Interferential laser therapy using two identical laser probes (810 nm, 100 mW, 15 sessions, 6 J/point)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional laser therapy with one live probe and one dummy probe (810 nm, 100 mW, 15 sessions, 6 J/point)
Number of subjects: 152
Study: 16685050

Group type: EXPERIMENTAL
Intervention: Brown diet (BD) rich in Maillard reaction products (MRPs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: White diet (WD) poor in Maillard reaction products (MRPs)
Number of subjects: 18
Study: 15566392

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of triclabendazole for 1 day (single-dose)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of triclabendazole for 2 days (double-dose)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of triclabendazole for 3 days (triple-dose)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study: 11780767

Group type: EXPERIMENTAL
Intervention: Thermography analyzed in conjunction with an artificial neural network (ANN) for breast cancer diagnosis.
Number of subjects: 0
Study: 9413756

Group type: EXPERIMENTAL
Intervention: Active nephrolithiasis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-active nephrolithiasis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50
Study: 8216115

Group type: EXPERIMENTAL
Intervention: Intrauterine catheters with titrated oxytocin to achieve the 75th percentile of uterine activity
Number of subjects: 239

Group type: COMPARATOR
Intervention: External tocography with titrated oxytocin to achieve 6 to 7 contractions per 15 minutes each lasting > 40 seconds
Number of subjects: 239
Study: 31219175

Group type: EXPERIMENTAL
Intervention: Adult Day Services (ADS) use (yes)
Number of subjects: 509

Group type: COMPARATOR
Intervention: No Adult Day Services use (no)
Number of subjects: 509
Study: 29996882

Group type: EXPERIMENTAL
Intervention: Tiao-Chang Ke-Min (TCKM) granules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26963615

Group type: EXPERIMENTAL
Intervention: Unipolar RF‐based device for home use
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24211112

Group type: EXPERIMENTAL
Intervention: Integrated self-care intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study: 22472791

Group type: EXPERIMENTAL
Intervention: 7.5 μg antigen with a full (9.75 mg) adjuvant dose
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: 3.75 μg antigen with a half (4.875 mg) adjuvant dose
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Both vaccine formulations
Number of subjects: 423
Study: 20973714

Group type: EXPERIMENTAL
Intervention: Electronic Monitoring (EM)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pill Counts
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Parent Medication Diary
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Patient Medication Diary
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: EM Adherent Group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: EM Nonadherent Group
Number of subjects: 31
Study: 18258801

Group type: EXPERIMENTAL
Intervention: Hypoxemia (mean nadir Po(2) 5.8 +/- 0.5 kPa)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (mean nadir plasma glucose 2.7 +/- 0.5 mmol/l)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoglycemic normoxia (control)
Number of subjects: 20
Study: 15930210

Group type: EXPERIMENTAL
Intervention: Dopamine (DP) at doses of 2.5, 5, 7.5, or 10 microg/kg per minute; n = 28
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Epinephrine (EP) at doses of 0.125, 0.250, 0.375, or 0.5 microg/kg per minute; n = 32
Number of subjects: 59
Study: 12957457

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (4.5, 6.75, 9.0, 12.0, 13.5, and 15.0 microg/kg) administered every 3 weeks for 12 weeks
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 9888119

Group type: EXPERIMENTAL
Intervention: True acupuncture (Ac)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Sham acupuncture (sham Ac)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Conventional treatment without Ac
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: True acupuncture (Ac) at three dose levels (28, 16, or 8 treatments)
Number of subjects: 438
Study: 8894955

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behaviour therapy (CBT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Relaxation training (Control)
Number of subjects: 53
Study: 1355426

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0
Study: 6682336

Group type: EXPERIMENTAL
Intervention: Oestradiol (50 mg) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oestradiol (50 mg) and testosterone (100 mg)
Number of subjects: 40
Study: 31662354

Group type: EXPERIMENTAL
Intervention: Non-interventional studies
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Randomised trials
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Spontaneous reports
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Changes to product information
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Marketing authorisation withdrawal or suspension
Number of subjects: 52
Study: 29901815

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks
Number of subjects: 2176

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks
Number of subjects: 2176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2176
Study: 27367995

Group type: EXPERIMENTAL
Intervention: Public Reporting of Health Care Performance (PRHCP)
Number of subjects: 748632
Study: 24945393

Group type: EXPERIMENTAL
Intervention: Metal staples (Leukosan Skin Stapler)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional continuous Donati suture
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metal staples
Number of subjects: 72
Study: 22046977

Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin-6 (IL-6) levels obtained 24-48 hours before delivery
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Maternal serum interleukin-6 (IL-6) levels obtained 48-72 hours before delivery
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: IL-6 level of 1.98 pg/ml
Number of subjects: 39
Study: 19384220

Group type: EXPERIMENTAL
Intervention: Daily bathing with chlorhexidine solution
Number of subjects: 0
Study: 17082978

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention for anger management (6 sessions of 2 hours each)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 45
Study: 15345983

Group type: EXPERIMENTAL
Intervention: Less Invasive Stabilization System (L.I.S.S.) plating
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: L.I.S.S plate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard double plate construct
Number of subjects: 38
Study: 11583367

Group type: EXPERIMENTAL
Intervention: Terazosine 2 mg/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: COMPARATOR
Intervention: Comparison between Terazosine and Placebo
Number of subjects: 91
Study: 9555827

Group type: EXPERIMENTAL
Intervention: Advanced Trauma Life Support (ATLS) training
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Advanced Trauma Life Support (ATLS) audit
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no ATLS training)
Number of subjects: 88
Study: 7734784

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Dietary manipulation for the first 4 weeks of life
Number of subjects: 926
Study: 2736104

Group type: EXPERIMENTAL
Intervention: Well-differentiated tumour
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Papillary tumour
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Aggressive tumour pattern
Number of subjects: 276

Group type: COMPARATOR
Intervention: Non-aggressive tumour pattern
Number of subjects: 276
Study: 1091993

Group type: EXPERIMENTAL
Intervention: Motorised foot mover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumatic compression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coumadin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium pentosan polysulphate
Number of subjects: 0
Study: 31953482

Group type: EXPERIMENTAL
Intervention: RC14-GR1
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Intermittent self-catheterisation (IMC)
Number of subjects: 207

Group type: COMPARATOR
Intervention: SPC or IDCs
Number of subjects: 207
Study: 30976888

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) with percutaneous kyphoplasty (PKP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (calcitriol and calcium carbonate D3 without ZOL)
Number of subjects: 101
Study: 28457344

Group type: EXPERIMENTAL
Intervention: Sapylin (STG)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Avitene
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 224
Study: 26545279

Group type: EXPERIMENTAL
Intervention: Buffered 2% lidocaine with 1:100,000 epinephrine buffered 9:1 with 8.4% sodium bicarbonate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-of-care 2% lidocaine with 1:100,000 epinephrine (unbuffered)
Number of subjects: 20
Study: 23025584

Group type: EXPERIMENTAL
Intervention: Stress condition (participants under stress)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No stress condition (participants not under stress)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Confederate's drinking condition: alcohol
Number of subjects: 106

Group type: COMPARATOR
Intervention: Confederate's drinking condition: soda
Number of subjects: 106
Study: 21475968

Group type: EXPERIMENTAL
Intervention: 6-month school-based physical activity program
Number of subjects: 457

Group type: COMPARATOR
Intervention: Observational group (control)
Number of subjects: 457
Study: 18697778

Group type: EXPERIMENTAL
Intervention: Active treatment for lower TJC patients
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Active treatment for higher TJC patients
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Control treatment for higher TJC patients
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Active treatment for lower SJC patients
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Active treatment for higher SJC patients
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Control treatment for higher SJC patients
Number of subjects: 2002
Study: 16860176

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine 35 microg/h
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine tablets (0.2 mg) as needed for breakthrough pain
Number of subjects: 239
Study: 14501247

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the sacral nerve roots
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical stimulation of the sacral nerve roots
Number of subjects: 0
Study: 11025242

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 43

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 43
Study: 9102740

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 2 weeks
Number of subjects: 163

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily for 2 weeks
Number of subjects: 163
Study: 1423952

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) performed 4-14 days after MI
Number of subjects: 87

Group type: COMPARATOR
Intervention: No PTCA (medical therapy alone)
Number of subjects: 87
Study: 3904378

Group type: EXPERIMENTAL
Intervention: Cholestyramine and diet
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo and diet
Number of subjects: 143